The medical treatment of colorectal cancer: Actual status and new developments

Hepato-Gastroenterology

Volumn 46, Issue 26, 1999, Pages 709-716

  Van Cutsem, Eric ^a   Peeters, Marc ^a   Verslype, Chris ^a   Filez, Ludo ^a   Haustermans, Karin ^a   Janssens, Jozef ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

5 FU; Chemotherapy; Colon cancer; Radiotherapy

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; ANTIINFECTIVE AGENT; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; ETHYNYLURACIL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PLATINUM COMPLEX; RALTITREXED; SPARFOSIC ACID; TEGAFUR; TETRAHYDROFOLIC ACID; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UFT; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CELL CYCLE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG COMBINATION; DRUG DEVELOPMENT; DRUG MECHANISM; GASTRODUODENAL ULCER; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; PORTAL VEIN BLOOD FLOW; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM CANCER; REGIONAL PERFUSION; SCLEROSING CHOLANGITIS; STOMATITIS; SURVIVAL RATE; TOXIC HEPATITIS; TUMOR CLASSIFICATION; TUMOR RECURRENCE; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; SURVIVAL RATE;

EID: 0032928639     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. 1 Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
2. 2 Advanced Colorectal Cancer Meta-Analysis Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12:960-969.
3. 3 Cunningham D, Findlay M: The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993; 29A:2077-2079.
4. 4 Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G et al: "Tomudex" (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31A:1945-1954.
5. 5 Cunningham D, Pyrhonen S, James D, et al: The value of second line chemotherapy after fluorouracil failure for patients with metastatic colorectal cancer: a randomized phase III trial of irinotecan versus supportive care. Proc Am Soc Oncol 1998; 17:1a.
6. 6 de Gramont A, Bossett JF, Milan C, et al: Randomized trial comparing monthly low dose leucovorin and 5-Fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French intergroup study. J Clin Oncol 1997; 15:808-815.
7. 7 de Gramont A, Figer A, Seymour M, et al: A randomized trial of Leucovorin (LV) and 5-Fluorouracil (5-FU) with or without oxaliplatin in advanced colorectal cancer. Proc Am Soc Clin Oncol 1998; 17:257a.
8. 8 Gerard A, Buyse M, Nordlinger B, Loygue J, Pene F, Kempf P, Bosset JF, Gignoux M, Arnaud JP, Desaive C, et al: Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomized study (EORTC). Ann Surg 1988; 208:606-614.
9. 9 Haller DG, Catalano PJ, Macdonald JS, Mayer RJ: Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: preliminary results of INT-0089. Proc Am Soc Clin Oncol 1996; 15:211. (Abstract 486)
10. 10 IMPACT Trial: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939-944.
11. 11 Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324:709-715.
12. 12 Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, et al: Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7:1447-1456.
13. 13 Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncology 1995; 13:1303-1311.
14. 14 Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95.
15. 15 Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emers WA, Tormey DC, Glick JH, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-326.
16. 16 Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 1994; 330:1136-1142.
17. 17 Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 1992; 10:904.
18. 18 O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331:502-507.
19. 19 O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295-300.
20. 20 Piedbois P, Buyse M, Gray, et al: Portal vein infusion in an effective adjuvant treatment for patients with colorectal cancer. Proc Am Soc Clin Oncol 1995; 14:192.
21. 21 Piedbois P, Buyse M, Rougier Ph, et al: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88:252.
22. 22 Rothenberg ML: CPT-11: An original spectrum of clinical activity. Seminars in Oncology 1996; 23:21-26.
23. 23 Rougier P, Bugat R: CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Seminars in Oncology 1996; 23:34-41.
24. 24 Rougier P, Sahmoud T, Nitti D, et al: Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomized trial. Lancet 1998; 351:1677-1681.
25. 25 Scheithauer W, Rosen H, Kornek G, Sebesta C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306:752-755.
26. 26 The Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336:980-987.
27. 27 Van Cutsem E: A glimpse of the future. New directions in the treatment of colorectal cancer. Eur J Cancer 1996; 32A:S23-S27.
28. 28 Van Cutsem E: Future developments with Tomudex (raltitrexed). Anti Cancer Drugs 1997; 8:S33-S38.
29. 29 Van Cutsem E, Bajetta E, Niederle N, et al: A phase III multicenter randomized trial comparing CPT-11 to infusional 5-FU regimen in patients with advanced colorectal cancer after 5-FU failure. Proc Am Soc Oncol 1998, 17:256a.
30. 30 Wolmark N, Rockette H, Mamounas EP, et al: The relative efficacy of 5-FU + leucovorin (FU-LV), 5-Fu + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon: First report of NSABP CO-4. Proc Am Soc Clin Oncol 1996, 15:205. (Abstract 460)
31. 31 Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M, Seymour I for the Tomudex Colorectal Study Group: ZD1694: A novel thymidilate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996; 14:716-721.